US regulators have approved oveporexton for narcolepsy type 1, the first medicine to restore the brain signal whose loss causes the disease rather than managing one symptom at a time.
About one person in 2,000 in the United States lives with narcolepsy type 1. Every medicine ever approved for it has treated a piece of the condition: a stimulant for the daytime sleepiness, a sedative for the broken nights, something else again for cataplexy, the sudden muscle weakness that strong emotion such as laughter can trigger. On 5 August 2026 the US Food and Drug Administration approved Orzeyful, or oveporexton, a tablet aimed at the cause instead. Narcolepsy type 1 begins when the brain loses the cells that make orexin, a chemical messenger that regulates wakefulness, sleep and muscle tone, and oveporexton switches on the receptor those cells would normally signal through.
How we know
The approval rests on two randomised, double-blind, placebo-controlled trials, FirstLight and RadiantLight, which enrolled 273 adults between them and ran for 12 weeks each. At the 2 mg dose both met their primary endpoint, the ability to stay awake during the day, and patients also reported less daytime sleepiness, fewer cataplexy attacks, and improvement in sleep paralysis, hallucinations and disrupted nighttime sleep. Neither trial has been published in a peer-reviewed journal yet; both have been presented at conferences and in Takeda's own announcements. The peer-reviewed evidence sits one step earlier, in a phase 2 trial published in the New England Journal of Medicine in May 2025, which randomised 112 adults to one of four oveporexton doses or placebo. Its main measure was the Maintenance of Wakefulness Test, a laboratory test of how long a person asked to stay awake actually manages it, scored from 0 to 40 minutes. After eight weeks the group taking 2 mg twice a day stayed awake 23.5 minutes longer on average than at the start, while the placebo group slipped by 1.2 minutes. On the Epworth Sleepiness Scale, a questionnaire running from 0 to 24 on which 10 or below counts as normal, that group fell by 13.8 points against 2.5 on placebo, and its weekly cataplexy episodes ran at 3.14 against 8.76 on placebo.
Why it matters
A medicine aimed at a cause is not the same as a cure. Oveporexton replaces the orexin signal; it does not bring back the cells that made it, so this is a daily tablet for life rather than a course of treatment. What changes is the target. Tiffany Farchione, who directs the psychiatry division at the FDA's Center for Drug Evaluation and Research, called it the first medicine that "impacts the underlying biology of the disease". The mechanism now has a medicine. Whether that medicine reaches a pharmacy shelf is a separate decision and it has not been made yet: oveporexton has been recommended for scheduling under the Controlled Substances Act and cannot lawfully be sold until the Drug Enforcement Administration rules on it, and the approval covers adults in the United States with narcolepsy type 1 alone.
The pivotal evidence is not yet peer-reviewed. FirstLight and RadiantLight have been presented at conferences and in Takeda's own releases, but the published trial is the smaller phase 2, and every trial in the programme was funded by Takeda. Both phase 3 trials ran 12 weeks, so nothing yet shows how the drug behaves over the years a lifelong condition demands. Side effects were common in the phase 2 trial: insomnia in 48 percent of participants, though most cases resolved within a week, urinary urgency in 33 percent and urinary frequency in 32 percent. This is a daily treatment and not a cure, the approval covers US adults with narcolepsy type 1 only and leaves type 2 untouched, and the medicine is not on pharmacy shelves while it awaits a DEA scheduling decision.
What is narcolepsy type 1?
It is a rare, lifelong neuropsychiatric sleep disorder affecting an estimated 1 in 2,000 people in the United States. It is caused by the loss of the brain cells that produce orexin, the chemical messenger that regulates wakefulness, sleep and muscle tone. Without it the brain struggles to stay alert or to hold the boundary between sleep and waking, producing excessive daytime sleepiness, cataplexy, sleep paralysis, hallucinations and disrupted nighttime sleep.
How is this different from existing narcolepsy treatments?
Existing treatments are stimulants or sedatives that manage individual symptoms rather than acting on the orexin system. Oveporexton activates the same brain receptor that orexin would normally stimulate, restoring the missing signal directly. The FDA describes it as the first medicine approved for narcolepsy type 1 as a complete disorder.
How strong is the evidence behind the approval?
Two randomised, placebo-controlled 12-week trials in 273 adults met their primary endpoint at the 2 mg dose, but neither has been published in a peer-reviewed journal yet. The published evidence is the earlier phase 2 trial in the New England Journal of Medicine, which followed 112 adults for eight weeks. Every trial in the programme was funded by Takeda, which makes the drug.
Can people get it now?
Not yet. Oveporexton has been recommended for scheduling under the Controlled Substances Act, and it will be lawful to market only after the Drug Enforcement Administration issues that scheduling decision. The approval also covers adults in the United States with narcolepsy type 1 only, and its safety and effectiveness have not been established in patients under 18.
- US Food and Drug Administration, FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms Primary
- US Food and Drug Administration, Novel Drug Approvals for 2026, entry 30: Orzeyful (oveporexton), approved 8/5/2026, to treat narcolepsy type 1 Primary
- New England Journal of Medicine, Oveporexton, an Oral Orexin Receptor 2 Selective Agonist, in Narcolepsy Type 1 Primary
- NeurologyLive, FDA Approves Orexin Agonist Oveporexton for Narcolepsy Type 1
One verified piece of progress, every other day.
Good news, checked against primary sources. Free.
Powered by Buttondown